The SGLT2 Comparison Was More Complicated The comparison against SGLT2 inhibitors is especially valuable because it places GLP-1 receptor agonists against another modern metabolic drug class rather than older diabetic therapies
It is listed as a monitoring issue rather than an outright prohibition, which distinguishes it from the gastrointestinal motility agents in the same table
However, safety assessments of oral semaglutide in the SOUL trial ( 5 Conclusion Semaglutide significantly reduces cardiovascular risk in patients with T2DM, primarily by improving MACE, nonfatal myocardial infarction, and revascularization outcomes, while modestly lowering HF hospitalization risk
Like any medication, it may have potential side effects, which will be discussed with you by your healthcare provider
Personalized Compounded Tirzepatide program pricing Your monthly cost reflects your program and your personalized dosage